Pfizer Corporation

Bristol-myers Squibb Compnay

Medimmune Limited

University of California

Yanli Wu

James David Marks

Haichun Huang

Arvind Rajpal

Brigitte Devaux

Peter Brams

Heidi N Leblanc

Kristopher Toy

Ronald P Gladue

Wei Liao

Jing Min

William Dall'Acqua

Jianlong Lou

Jody Lynn Baron

Barrett Richard Thiele

Yi Wu

Rory Francis Finn

Ping Tsui

Stephen L Nishimura

Timothy J Paradis

Martin Borrok, Iii

Anthony Cormier

Nurten Beyaz-Kavuncu

Lynne Murray

Ronald Paul Gladue

Timothy Joseph Paradis

The present invention provides molecules, including proteins, more particularly, immunoglobulins whose in vivo half-lives are altered (increased or decreased) by the presence of an IgG constant domain, or FcRn binding fragment thereof (e.g., an Fc region or hinge-Fc region) (e.g., from a human IgG, e.g., human IgG1), that have modifications of one or more of amino acid residues in at least the CH3 domain.

Molecules with altered neonate Fc receptor binding having enhanced therapeutic and diagnostic properties

The present disclosure provides isolated binding molecules that bind to the human OX40R, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.

Binding molecules to the human OX40 receptor

Growing community of inventors

Ballwin, MO, United States of America

Yanli Wu